AR130983A1 - Derivados de triazinona inhibidores de nlrp3 - Google Patents

Derivados de triazinona inhibidores de nlrp3

Info

Publication number
AR130983A1
AR130983A1 ARP230102981A ARP230102981A AR130983A1 AR 130983 A1 AR130983 A1 AR 130983A1 AR P230102981 A ARP230102981 A AR P230102981A AR P230102981 A ARP230102981 A AR P230102981A AR 130983 A1 AR130983 A1 AR 130983A1
Authority
AR
Argentina
Prior art keywords
disease
disorder
methyl
condition
triazin
Prior art date
Application number
ARP230102981A
Other languages
English (en)
Inventor
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina Mesch
Jonathan Martin Shannon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR130983A1 publication Critical patent/AR130983A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto seleccionado de 6-[[(3R)-1-etil-3-piperidil]amino]-3-(4-hidroxiindan-5-il)-4-metil-1,2,4-triazin-5-ona; 6-[[(3R)-1-etil-3-piperidil]amino]-3-(2-hidroxi-3-biciclo[4.2.0]octa-1,3,5-trienil)-4-metil-1,2,4-triazin-5-ona; 6-[[(3R)-1-etil-3-piperidil]-metil-amino]-3-(4-hidroxiindan-5-il)-4-metil-1,2,4-triazin-5-ona; o una sal farmacéuticamente aceptable de aquel. Reivindicación 6: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4 para su uso en el tratamiento o prevención de una enfermedad, trastorno o afección, en donde la enfermedad, trastorno o afección es sensible a la inhibición de NLRP3. Reivindicación 9: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4, para el tratamiento o profilaxis de una enfermedad, trastorno o afección seleccionada de asma o EPOC. Reivindicación 10: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4 para el tratamiento o profilaxis de una enfermedad, trastorno o afección seleccionada de enfermedad de Alzheimer y enfermedad de Parkinson.
ARP230102981A 2022-11-09 2023-11-07 Derivados de triazinona inhibidores de nlrp3 AR130983A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22206287 2022-11-09

Publications (1)

Publication Number Publication Date
AR130983A1 true AR130983A1 (es) 2025-02-05

Family

ID=84330665

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102981A AR130983A1 (es) 2022-11-09 2023-11-07 Derivados de triazinona inhibidores de nlrp3

Country Status (15)

Country Link
US (1) US20260176250A1 (es)
EP (1) EP4615575A1 (es)
JP (1) JP2025537237A (es)
KR (1) KR20250093508A (es)
CN (1) CN120282957A (es)
AR (1) AR130983A1 (es)
AU (1) AU2023376402A1 (es)
CL (1) CL2025001320A1 (es)
CO (1) CO2025005534A2 (es)
CR (1) CR20250186A (es)
IL (1) IL319009A (es)
MX (1) MX2025004961A (es)
PE (1) PE20251675A1 (es)
TW (1) TW202428281A (es)
WO (1) WO2024099996A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
JP2026509587A (ja) * 2023-03-23 2026-03-19 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 トリアジン化合物およびその使用
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021219784A1 (en) * 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv New triazinoindole compounds

Also Published As

Publication number Publication date
CL2025001320A1 (es) 2025-07-11
JP2025537237A (ja) 2025-11-14
AU2023376402A1 (en) 2025-02-13
CO2025005534A2 (es) 2025-05-19
MX2025004961A (es) 2025-06-02
IL319009A (en) 2025-04-01
KR20250093508A (ko) 2025-06-24
US20260176250A1 (en) 2026-06-25
CR20250186A (es) 2025-06-26
CN120282957A (zh) 2025-07-08
TW202428281A (zh) 2024-07-16
PE20251675A1 (es) 2025-06-30
WO2024099996A1 (en) 2024-05-16
EP4615575A1 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
MX2023007192A (es) Inhibidores de prmt5.
GEP20257750B (en) 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
MX2022010011A (es) Inhibidores de prmt5 novedosos.
PE20251675A1 (es) Derivados de triazinona como inhibidores de nlrp3
MX2021015262A (es) Inhibidores de prmt5.
PH12021500049A1 (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
MX2007013216A (es) Derivados de amida substituida como inhibidores de la proteina de cinasa.
MA30208B1 (fr) Derives de pyrimidine utilises en tant qu'inhibiteurs de kinase pi -3
CR9984A (es) Método de inhibición de cinasa de tirosina cinasa 3 similar a fms
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EA201171213A1 (ru) Ингибитор р38 мар киназы
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
BRPI0612072A2 (pt) inibidores da aspartil protease
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
PH12019502601A1 (en) Therapeutic compounds and compositions, and methods of use thereof
BRPI0607433A2 (pt) composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um composto
MX2018014425A (es) Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
JOP20250208A1 (ar) مشتقات فينيل بيبريدين كمثبطات لبروتين ربط جلوتامينيل - ببتيد سيكلو ترانسفيراز وجلوتامينيل - ببتيد سيكلو ترانسفيراز
MX2021012392A (es) Compuestos, composiciones y metodos.
UA107106C2 (uk) УРЕТАНИ, СЕЧОВИНИ, АМІДИ ТА РОДИННІ ІНГІБІТОРИ ФАКТОРА Xа